nodes	percent_of_prediction	percent_of_DWPC	metapath
Valrubicin—TOP2A—malignant glioma	0.985	1	CbGaD
Valrubicin—Daunorubicin—POR—malignant glioma	0.00221	0.241	CrCbGaD
Valrubicin—Doxorubicin—POR—malignant glioma	0.0018	0.196	CrCbGaD
Valrubicin—Idarubicin—TOP2A—malignant glioma	0.00166	0.181	CrCbGaD
Valrubicin—Epirubicin—TOP2A—malignant glioma	0.00126	0.137	CrCbGaD
Valrubicin—Daunorubicin—TOP2A—malignant glioma	0.000889	0.0969	CrCbGaD
Valrubicin—Doxorubicin—TOP2A—malignant glioma	0.000721	0.0786	CrCbGaD
Valrubicin—Doxorubicin—CYP2B6—malignant glioma	0.000641	0.0699	CrCbGaD
Valrubicin—TOP2A—Gastric Cancer Network 1—H3F3A—malignant glioma	0.00021	0.0697	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—STMN1—malignant glioma	0.00015	0.0499	CbGpPWpGaD
Valrubicin—Urinary incontinence—Carmustine—malignant glioma	0.000141	0.0539	CcSEcCtD
Valrubicin—Urinary incontinence—Temozolomide—malignant glioma	0.000136	0.0521	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—FBXW7—malignant glioma	0.000132	0.0438	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BDKRB2—malignant glioma	0.000129	0.0429	CbGpPWpGaD
Valrubicin—TOP2A—Gastric Cancer Network 1—NOTCH1—malignant glioma	0.000109	0.0363	CbGpPWpGaD
Valrubicin—TOP2A—Gastric Cancer Network 1—APC—malignant glioma	0.000107	0.0355	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—malignant glioma	0.000104	0.0346	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—HES1—malignant glioma	9.84e-05	0.0327	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—NTRK3—malignant glioma	9.61e-05	0.0319	CbGpPWpGaD
Valrubicin—Dysuria—Temozolomide—malignant glioma	8.26e-05	0.0316	CcSEcCtD
Valrubicin—Hyperglycaemia—Carmustine—malignant glioma	8.25e-05	0.0316	CcSEcCtD
Valrubicin—Pneumonia—Carmustine—malignant glioma	8.2e-05	0.0314	CcSEcCtD
Valrubicin—Pollakiuria—Temozolomide—malignant glioma	8.16e-05	0.0313	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—STMN1—malignant glioma	8e-05	0.0266	CbGpPWpGaD
Valrubicin—Hyperglycaemia—Temozolomide—malignant glioma	7.97e-05	0.0305	CcSEcCtD
Valrubicin—Urinary tract infection—Carmustine—malignant glioma	7.93e-05	0.0303	CcSEcCtD
Valrubicin—Pneumonia—Temozolomide—malignant glioma	7.93e-05	0.0303	CcSEcCtD
Valrubicin—Urinary tract infection—Temozolomide—malignant glioma	7.66e-05	0.0293	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—malignant glioma	7.43e-05	0.0247	CbGpPWpGaD
Valrubicin—Oedema peripheral—Carmustine—malignant glioma	7.21e-05	0.0276	CcSEcCtD
Valrubicin—Oedema peripheral—Temozolomide—malignant glioma	6.97e-05	0.0267	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—TUBG2—malignant glioma	6.4e-05	0.0213	CbGpPWpGaD
Valrubicin—Back pain—Carmustine—malignant glioma	6.16e-05	0.0236	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PLK1—malignant glioma	6.07e-05	0.0202	CbGpPWpGaD
Valrubicin—Back pain—Temozolomide—malignant glioma	5.96e-05	0.0228	CcSEcCtD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—malignant glioma	5.9e-05	0.0196	CbGpPWpGaD
Valrubicin—Anaemia—Carmustine—malignant glioma	5.89e-05	0.0225	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—malignant glioma	5.75e-05	0.0191	CbGpPWpGaD
Valrubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—malignant glioma	5.72e-05	0.019	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TUBG2—malignant glioma	5.72e-05	0.019	CbGpPWpGaD
Valrubicin—Ill-defined disorder—Temozolomide—malignant glioma	5.71e-05	0.0219	CcSEcCtD
Valrubicin—Anaemia—Temozolomide—malignant glioma	5.69e-05	0.0218	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—MYC—malignant glioma	5.58e-05	0.0185	CbGpPWpGaD
Valrubicin—Malaise—Temozolomide—malignant glioma	5.55e-05	0.0213	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—EGFR—malignant glioma	5.45e-05	0.0181	CbGpPWpGaD
Valrubicin—Myalgia—Carmustine—malignant glioma	5.43e-05	0.0208	CcSEcCtD
Valrubicin—Chest pain—Carmustine—malignant glioma	5.43e-05	0.0208	CcSEcCtD
Valrubicin—Myalgia—Temozolomide—malignant glioma	5.24e-05	0.0201	CcSEcCtD
Valrubicin—Discomfort—Temozolomide—malignant glioma	5.18e-05	0.0198	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PML—malignant glioma	5.13e-05	0.017	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—PML—malignant glioma	4.92e-05	0.0164	CbGpPWpGaD
Valrubicin—Musculoskeletal discomfort—Carmustine—malignant glioma	4.74e-05	0.0181	CcSEcCtD
Valrubicin—TOP2A—Gastric Cancer Network 2—TP53—malignant glioma	4.58e-05	0.0152	CbGpPWpGaD
Valrubicin—Musculoskeletal discomfort—Temozolomide—malignant glioma	4.58e-05	0.0175	CcSEcCtD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2B—malignant glioma	4.43e-05	0.0147	CbGpPWpGaD
Valrubicin—Feeling abnormal—Carmustine—malignant glioma	4.29e-05	0.0164	CcSEcCtD
Valrubicin—Gastrointestinal pain—Carmustine—malignant glioma	4.25e-05	0.0163	CcSEcCtD
Valrubicin—Feeling abnormal—Temozolomide—malignant glioma	4.14e-05	0.0159	CcSEcCtD
Valrubicin—Abdominal pain—Carmustine—malignant glioma	4.11e-05	0.0157	CcSEcCtD
Valrubicin—Body temperature increased—Carmustine—malignant glioma	4.11e-05	0.0157	CcSEcCtD
Valrubicin—Gastrointestinal pain—Temozolomide—malignant glioma	4.11e-05	0.0157	CcSEcCtD
Valrubicin—Abdominal pain—Temozolomide—malignant glioma	3.97e-05	0.0152	CcSEcCtD
Valrubicin—Body temperature increased—Temozolomide—malignant glioma	3.97e-05	0.0152	CcSEcCtD
Valrubicin—Asthenia—Carmustine—malignant glioma	3.73e-05	0.0143	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—NTRK1—malignant glioma	3.65e-05	0.0121	CbGpPWpGaD
Valrubicin—Asthenia—Temozolomide—malignant glioma	3.61e-05	0.0138	CcSEcCtD
Valrubicin—Diarrhoea—Carmustine—malignant glioma	3.56e-05	0.0136	CcSEcCtD
Valrubicin—Pruritus—Temozolomide—malignant glioma	3.56e-05	0.0136	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—NTRK1—malignant glioma	3.5e-05	0.0116	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—malignant glioma	3.5e-05	0.0116	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—RAF1—malignant glioma	3.48e-05	0.0116	CbGpPWpGaD
Valrubicin—Dizziness—Carmustine—malignant glioma	3.44e-05	0.0132	CcSEcCtD
Valrubicin—Diarrhoea—Temozolomide—malignant glioma	3.44e-05	0.0132	CcSEcCtD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—malignant glioma	3.39e-05	0.0113	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN2B—malignant glioma	3.36e-05	0.0112	CbGpPWpGaD
Valrubicin—Dizziness—Temozolomide—malignant glioma	3.32e-05	0.0127	CcSEcCtD
Valrubicin—Vomiting—Carmustine—malignant glioma	3.31e-05	0.0127	CcSEcCtD
Valrubicin—Rash—Carmustine—malignant glioma	3.28e-05	0.0126	CcSEcCtD
Valrubicin—Dermatitis—Carmustine—malignant glioma	3.28e-05	0.0125	CcSEcCtD
Valrubicin—Headache—Carmustine—malignant glioma	3.26e-05	0.0125	CcSEcCtD
Valrubicin—Vomiting—Temozolomide—malignant glioma	3.2e-05	0.0122	CcSEcCtD
Valrubicin—Rash—Temozolomide—malignant glioma	3.17e-05	0.0121	CcSEcCtD
Valrubicin—Dermatitis—Temozolomide—malignant glioma	3.17e-05	0.0121	CcSEcCtD
Valrubicin—Headache—Temozolomide—malignant glioma	3.15e-05	0.0121	CcSEcCtD
Valrubicin—Nausea—Carmustine—malignant glioma	3.09e-05	0.0118	CcSEcCtD
Valrubicin—TOP2A—Circadian rythm related genes—NCOR1—malignant glioma	3.06e-05	0.0102	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PDGFRA—malignant glioma	3.05e-05	0.0101	CbGpPWpGaD
Valrubicin—Nausea—Temozolomide—malignant glioma	2.99e-05	0.0114	CcSEcCtD
Valrubicin—TOP2A—Cell Cycle, Mitotic—PLK1—malignant glioma	2.94e-05	0.00976	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—HIST1H3B—malignant glioma	2.91e-05	0.00967	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	2.73e-05	0.00906	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—PLK1—malignant glioma	2.63e-05	0.00873	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—HIST1H3B—malignant glioma	2.6e-05	0.00865	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—malignant glioma	2.54e-05	0.00843	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	2.44e-05	0.00812	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—malignant glioma	2.44e-05	0.00812	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	2.37e-05	0.00786	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	2.34e-05	0.00777	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—H3F3A—malignant glioma	2.25e-05	0.00747	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—PPARG—malignant glioma	2.19e-05	0.00729	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—YWHAE—malignant glioma	2.17e-05	0.0072	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—H3F3A—malignant glioma	2.01e-05	0.00668	CbGpPWpGaD
Valrubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—malignant glioma	2.01e-05	0.00667	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	1.99e-05	0.00662	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—YWHAE—malignant glioma	1.94e-05	0.00643	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BCL2—malignant glioma	1.89e-05	0.00629	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	1.86e-05	0.00619	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	1.86e-05	0.00617	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	1.84e-05	0.00611	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—malignant glioma	1.8e-05	0.00597	CbGpPWpGaD
Valrubicin—TOP2A—Mitotic G1-G1/S phases—MYC—malignant glioma	1.72e-05	0.00571	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	1.67e-05	0.00554	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN2B—malignant glioma	1.63e-05	0.00541	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	1.57e-05	0.00521	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—PTEN—malignant glioma	1.5e-05	0.005	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—BRCA2—malignant glioma	1.47e-05	0.00488	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN2B—malignant glioma	1.45e-05	0.00483	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	1.42e-05	0.0047	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—BIRC5—malignant glioma	1.4e-05	0.00466	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	1.3e-05	0.00433	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	1.27e-05	0.00423	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—BIRC5—malignant glioma	1.25e-05	0.00417	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TERT—malignant glioma	1.22e-05	0.00404	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	1.21e-05	0.00403	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	1.2e-05	0.004	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	1.11e-05	0.00367	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	1.07e-05	0.00355	CbGpPWpGaD
Valrubicin—TOP2A—Circadian rythm related genes—TP53—malignant glioma	1.03e-05	0.00341	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—malignant glioma	9.3e-06	0.00309	CbGpPWpGaD
Valrubicin—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	9.03e-06	0.003	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—CDKN2A—malignant glioma	8.32e-06	0.00276	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MDM2—malignant glioma	8.07e-06	0.00268	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle, Mitotic—MYC—malignant glioma	6.3e-06	0.00209	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—MYC—malignant glioma	5.64e-06	0.00187	CbGpPWpGaD
Valrubicin—TOP2A—Cell Cycle—TP53—malignant glioma	4.63e-06	0.00154	CbGpPWpGaD
